Bayer's Pivotal Week: A Clinical Win Meets Legal and Financial Scrutiny

Bayer shares surge 95% in a year. Key events this week: stroke drug breakthrough data, Supreme Court glyphosate hearing, and Annual General Meeting.

Bayer shares, trading at €41.10, find themselves at a critical juncture. The stock has nearly doubled from its 52-week low of just over €21 euros, marking a 95 percent surge over the past twelve months. This remarkable recovery now faces a concentrated test of the company's operational, legal, and governance direction.

The most significant scientific news arrived on April 16th with the full publication of the OCEANIC-STROKE Phase III trial in the New England Journal of Medicine. For the first time in the history of FXIa inhibitors, a drug—Bayer's asundexian—proved effective in preventing ischemic strokes without increasing bleeding risk. Among 12,327 participants, 6.2 percent in the asundexian group suffered a recurrent stroke, compared to 8.4 percent on placebo, a 26 percent reduction. The drug's mechanism, blocking the Factor XIa protein involved in clotting but not in natural bleeding defense, represents a potential breakthrough. While not yet approved and still undergoing regulatory review, the data provide a crucial boost to Bayer's pharmaceutical pipeline.

Investor attention now shifts sharply to a series of imminent events. On April 24th, the virtual Annual General Meeting will see shareholders vote on a nominal dividend of €0.11 per share and elect new supervisory board members, with Marcel Smits and Alfred Stern slated to replace Paul Achleitner and Colleen Goggins. Preceding this, on April 22nd, the publication of speeches by CEO Bill Anderson and Supervisory Board Chairman Norbert Winkeljohann will offer the last official commentary from leadership before a quiet period begins ahead of mid-May's quarterly report.

The most consequential near-term event, however, is legal. On April 27th, the U.S. Supreme Court will hear arguments regarding the herbicide glyphosate. Analysts view this as a potential structural turning point. DZ Bank's Peter Spengler notes a favorable ruling could establish federal law preemption over state warning label requirements, significantly weakening the foundation for future litigation. A final decision is expected by June 2026.

Analyst sentiment has turned notably more positive in anticipation. Deutsche Bank dramatically raised its price target from €23 to €43, maintaining a "Hold" rating. Analyst Virginie Boucher-Ferte forecasts 3.6 percent organic growth for the upcoming quarter, driven by the agricultural business. UBS reaffirmed its "Buy" recommendation with a €52 target, focusing on growth dynamics for pharmaceutical products Nubeqa and Kerendia. DZ Bank itself upgraded the stock from "Sell" to "Hold," lifting its fair value estimate to €44.

The company's operational turnaround, targeting an EBITDA before special items of €9.6 to €10.1 billion for 2026, faces its next practical test with the May quarterly figures. For now, the share price holds steady just above the psychologically important €40 mark, having gained roughly eight percent since the start of the year. The outcome of this pivotal week will determine whether the stock challenges its yearly high near €49 or faces renewed pressure.